Nexipel20 mg

Nexipel is a standardized herbal (phytopharmaceutical) root extract used for the symptomatic treatment of respiratory tract conditions. Indications are classified below by strength of supporting evidence.

Guideline/Evidence-Supported Uses

• Acute bronchitis: Several randomized controlled trials and a Cochrane-reviewed body of evidence support use of Nexipel for modest reduction in the duration and severity of cough, sputum production, and other symptoms of uncomplicated acute bronchitis in adults and children.
• Common cold / uncomplicated upper respiratory tract infection (URTI): Used for symptomatic relief of nasal congestion, sore throat, and cough associated with viral URTIs.

Adjunct Use

• May be used as an adjunct to supportive care (rest, hydration, analgesics/antipyretics) for uncomplicated viral respiratory infections.

Important Limitation

Nexipel is not an antibiotic and is not a substitute for antimicrobial therapy when a bacterial infection requiring antibiotics (e.g., streptococcal pharyngitis, bacterial pneumonia, bacterial sinusitis) has been diagnosed by a physician.

Each dose (oral drops, film-coated tablet, or syrup, depending on formulation) contains a standardized liquid extract of Pelargonium Sidoides root (commonly standardized as extract EPs 7630, extraction solvent 11% ethanol/water), a herbal preparation traditionally known by the trade name Umckaloabo.

Nexipel is an herbal (geranium-family) medicinal plant native to South Africa and Lesotho. Its root extract has a long history of traditional use for respiratory ailments and has since been studied in clinical trials and standardized as a phytopharmaceutical preparation (commonly designated EPs 7630).

Nexipel root extract contains coumarins, phenolic acids, and proanthocyanidins that are believed to underlie its antibacterial, antiviral, and immunomodulatory activity. It is marketed as an over-the-counter herbal remedy for acute bronchitis and common-cold symptoms rather than as a prescription antimicrobial.

Herbal medicinal product / Phytotherapeutic agent for respiratory tract disorders (Nexipel root extract)

Mechanism of Action

The precise mechanism of Pelargonium Sidoides extract is not fully elucidated, but in-vitro and animal studies suggest several complementary actions:

• Antibacterial: Interferes with bacterial adhesion to respiratory epithelial cells and has direct antibacterial activity against some respiratory pathogens.
• Antiviral: Inhibits replication of some respiratory viruses in laboratory studies and stimulates interferon and other antiviral cytokine pathways.
• Immunomodulatory: Activates macrophages, stimulates nitric oxide and cytokine production (e.g., TNF-alpha, interferon-beta), and enhances local mucosal immune defenses.
• Mucociliary: Increases ciliary beat frequency, promoting clearance of mucus and pathogens from the respiratory tract.

Pharmacokinetics

As a complex multi-component herbal extract, formal pharmacokinetic parameters (absorption, distribution, metabolism, elimination) for Pelargonium Sidoides have not been comprehensively characterized in humans in the way they would be for a single-molecule drug.

Nexipel oral drops may be taken directly by mouth or diluted in a small amount of water or juice; shake the bottle well before each use. Tablets/syrup should be taken with a glass of water. Nexipel may be taken with or without food. Do not exceed the recommended dose or duration without medical advice.

Anticoagulants and antiplatelet agents (e.g., warfarin, heparin, aspirin, clopidogrel): Nexipel has a theoretical antiplatelet/anticoagulant-potentiating effect, and rare case reports describe increased bleeding tendency with concurrent use. Use with caution and monitor for signs of bleeding if Nexipel is combined with these agents; consult a physician before co-administration.

No other well-verified, clinically significant drug interactions have been established for Nexipel. Theoretical interactions with other herbal products affecting platelet function or hepatic metabolism cannot be excluded; inform your physician of all medicines and supplements taken concurrently with Nexipel.

Common

• Mild gastrointestinal upset (nausea, dyspepsia, mild abdominal discomfort, loose stools)

Uncommon/Rare

• Hypersensitivity reactions: skin rash, urticaria, pruritus, and rarely angioedema
• Mild bleeding tendencies (e.g., gingival bleeding, epistaxis) reported rarely, particularly with concomitant anticoagulant/antiplatelet use — see Interactions
• Rare reports of elevated liver enzymes or hepatotoxicity associated with Nexipel; discontinue and seek medical attention if signs of liver injury (jaundice, dark urine, unusual fatigue, right upper abdominal pain) occur — see Contraindications

Pregnancy: Data on the use of Nexipel in pregnancy are limited. As a precaution, Nexipel should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether components of Nexipel pass into human breast milk. Use during breastfeeding only after consulting a physician, weighing benefits against unknown risks to the infant.

• Bleeding risk: Use Nexipel with caution in patients with known bleeding disorders or those taking anticoagulant/antiplatelet medicines, due to a theoretical increased bleeding risk (see Interactions).
• Liver monitoring: Discontinue Nexipel and seek medical advice promptly if signs of liver injury develop (yellowing of skin/eyes, dark urine, persistent nausea, unusual tiredness, right upper abdominal pain) — see Contraindications for hepatic impairment.
• When to stop and seek medical care: Discontinue Nexipel and consult a physician if symptoms worsen, fail to improve within about one week, or if fever, chest pain, difficulty breathing, or purulent (colored) sputum develop, as these may indicate a bacterial infection requiring antibiotics.
• Not an antibiotic: Nexipel is a herbal symptomatic treatment, not an antimicrobial; it does not treat bacterial infections directly. Appropriate use for viral bronchitis/URTI symptoms may help reduce unnecessary antibiotic use, but any decision to start, stop, or avoid antibiotics should be made by a physician.

Limited data exist on Nexipel overdose in humans. In the event of a suspected overdose of Nexipel, seek immediate medical attention or contact a poison control center/emergency services. Symptomatic and supportive care should be provided as directed by a healthcare professional; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Keep out of reach of children.

• Elderly: No specific dose adjustment has been established for Nexipel in elderly patients; use with the same caution as in other adults, particularly regarding bleeding risk and hepatic monitoring.
• Renal impairment: No well-established dose adjustment is available for Nexipel in renal impairment; use with caution and medical supervision.
• Hepatic impairment: Nexipel is contraindicated in severe hepatic impairment/active liver disease — see Contraindications.
• Pediatric population: See Pediatric Uses.
• Pregnancy and lactation: See Pregnancy and Lactation.

Nexipel is typically used for 7–10 days per episode of acute bronchitis or common-cold symptoms. If there is no improvement within about one week, or if symptoms worsen, treatment should be stopped and a physician consulted rather than continuing or repeating courses of Nexipel without medical supervision.

Herbal medicinal product; phytotherapeutic respiratory-tract preparation derived from Pelargonium Sidoides root extract (EPs 7630)

Pelargonium Sidoides root extract exerts antibacterial (anti-adhesive), antiviral, immunomodulatory (macrophage/interferon activation), and mucociliary-clearance-enhancing effects on the respiratory tract mucosa, which together are believed to reduce the duration and severity of bronchitis and cold symptoms.

Nexipel liquid preparations have been studied and used in children from 1 year of age for acute bronchitis and cold symptoms, at reduced, age-adjusted doses (see Dosage and Administration). Use in infants under 1 year of age is not recommended, as safety and efficacy have not been established in this age group. Tablet/capsule formulations of Nexipel are generally intended for adolescents ≥ 12 years and adults who can swallow solid dosage forms. A pediatrician should be consulted before giving Nexipel to any child, particularly those with bleeding disorders or liver disease.